| Patient | Vivekananda |
|---|---|
| Date of birth | 1991-01-12 |
| Identifiers | MRN HR-NI032-SYN; SSN (made up) 000-32-9014 |
| Document date | 2026-11-01 |
| Author | Anjali Thornbury-Mensah, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
New patient visit for thirst, frequent urination, tiredness and weight loss in a 35-year-old monk told of diabetes a year ago and never tested: examination, random glucose and urine tests, and planning of fasting tests to confirm and classify diabetes; long-standing insomnia; raised blood pressure. Concerns: He is thirsty, up at night to pass urine, tired and losing weight, and wants to know whether he truly has diabetes and what kind; He wants any treatment to fit his monastic life: his diet, his fasts and his travel; He has never been able to fall asleep easily, and broken nights now leave him exhausted. [S]
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Metformin extended-release 500 mg tablets: two tablets (1000 mg) with the evening meal, starting with one for the first week | 1000 mg with the evening meal | Oral route | 2026-02-16 to 2026-03-23 | completed | S |
| Metformin extended-release 500 mg tablets: four tablets (2000 mg) with the evening meal; on fast days with the meal that ends the fast; hold if vomiting, diarrhea or unable to drink | 2000 mg with the evening meal | Oral route | 2026-03-23 | active | S |
| Losartan 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-09 | active | S |
| Atorvastatin 10 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-03-23 | active | S |
| Prednisone 20 mg oral tablet, two tablets (40 mg) each morning for five days | 40 mg each morning for five days | Oral route | 2026-10-20 to 2026-10-24 | completed | S |
| Budesonide-formoterol 160/4.5 mcg inhaler with a spacer, one inhalation as needed for wheeze or breathlessness, no more than 12 inhalations a day, until lung function testing | One inhalation as needed | Respiratory tract route | 2026-10-20 to 2026-10-27 | completed | S |
| Empagliflozin 10 mg oral tablet, one tablet each morning; skip it on any day of fasting without water, and stop it when unable to eat or drink | One tablet daily | Oral route | 2026-10-27 | active | S |
| Budesonide-formoterol 160/4.5 mcg inhaler with a spacer as maintenance and reliever (GINA track 1, step 3): one inhalation twice daily and one as needed, no more than 12 inhalations a day | One inhalation twice daily plus one as needed | Respiratory tract route | 2026-10-27 | active | S |
| Procedure | Dates | Status | Evidence |
|---|---|---|---|
| Comprehensive diabetic foot examination: skin intact; pulses present; 10-g monofilament and vibration sense normal at all sites | 2026-02-16 to 2026-02-16 | completed | S |
| Diabetes self-management education and medical nutrition therapy referral: a dietitian visit to build a meal plan around his monastery diet and fasts | 2026-02-16 to 2026-02-16 | completed | S |
| Advance care planning conversation, about 20 minutes, with his consent | 2026-03-09 to 2026-03-09 | completed | S |
| Diabetic retinopathy screening with retinal photographs of both eyes: no retinopathy; no macular edema | 2026-03-23 to 2026-03-23 | completed | S |
| Chest X-ray, posteroanterior and lateral: mild hyperinflation; heart size normal; no pulmonary edema, effusion or consolidation | 2026-10-20 to 2026-10-20 | completed | S |
| Resting 12-lead ECG: sinus tachycardia at 106 per minute; normal axis and intervals; no ischemic change | 2026-10-20 to 2026-10-20 | completed | S |
| Spirometry before and 15 minutes after albuterol 400 mcg, with FeNO, interpreted with GLI Global race-neutral equations: FEV1 2.95 L (77 percent predicted) rising to 3.42 L (+470 mL, +16 percent); FEV1/FVC 0.66 before and 0.75 after; FeNO 44 ppb. Reversible airflow obstruction: asthma | 2026-10-27 to 2026-10-27 | completed | S |
| Written asthma action plan with peak flow zones (green above 470 L/min, yellow 300 to 470, red below 300, from his predicted value until a personal best is set), given and explained | 2026-10-27 to 2026-10-27 | completed | S |
| Inhaler technique with a spacer, taught and checked by teach-back: correct | 2026-10-27 to 2026-10-27 | completed | S |
| Date | Vaccine | Status | Evidence |
|---|---|---|---|
| 2026-02-16 | Influenza vaccine, this season | completed | S |
| 2026-02-16 | COVID-19 mRNA vaccine, this season's formula | completed | S |
| 2026-02-16 | Pneumococcal conjugate vaccine PCV20 | completed | S |
| 2026-03-09 | Tdap vaccine (no record of a tetanus vaccine in adulthood) | completed | S |
| 2026-03-09 | Hepatitis B vaccine (HepB-CpG), dose 1 of 2 | completed | S |
| 2026-10-27 | Hepatitis B vaccine (HepB-CpG), dose 2 of 2 | completed | S |
| 2026-10-27 | Influenza vaccine, the new season | completed | S |
| 2026-10-27 | COVID-19 mRNA vaccine, the new season's formula | completed | S |
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| March 1897 | Diabetes, as he described it in his letters, after his return to India at about 34; physicians advised the cool air of Darjeeling and rest; he wrote that eating only meat and drinking no water seemed the only way to prolong his life; how it was diagnosed is not recorded | D (CLM-0005) |
| May 29, 1897 | Lifelong difficulty falling asleep, in his own words: unable to sleep on getting into bed, tossing for at least two hours | D (CLM-0006) |
| Relative | Condition | Age at death | Evidence |
|---|---|---|---|
| family member | Diabetes, which he called "a hereditary foe"; no relative is named and no detail is recorded | D (CLM-0005) |
| Concern | Status | Evidence |
|---|---|---|
| He is thirsty, up at night to pass urine, tired and losing weight, and wants to know whether he truly has diabetes and what kind | active | S |
| He wants any treatment to fit his monastic life: his diet, his fasts and his travel | active | S |
| He has never been able to fall asleep easily, and broken nights now leave him exhausted | active | S |
Most recent measures: Glucose [Mass/volume] in Serum or Plasma 124 on 2026-10-27; Sodium [Moles/volume] in Serum or Plasma 136 on 2026-02-09; Potassium [Moles/volume] in Serum or Plasma 4.5 on 2026-10-27; Creatinine [Mass/volume] in Serum or Plasma 0.98 on 2026-10-27; Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M 103 on 2026-10-27; Hemoglobin [Mass/volume] in Blood 14.6 on 2026-02-09; Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] 1 on 2026-10-27; Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] 3 on 2026-03-09; Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] 2 on 2026-03-09; Total score [AUDIT-C] 0 on 2026-03-09; Maximum expiratory gas flow Respiratory system airway by Peak flow meter 330 on 2026-10-20; Hemoglobin A1c/Hemoglobin.total in Blood 6.9 on 2026-10-27; Glutamate decarboxylase 65 Ab [Units/volume] in Serum by Immunoassay 1.2 on 2026-02-16; C peptide [Mass/volume] in Serum or Plasma 2.6 on 2026-02-16; Albumin/Creatinine [Mass Ratio] in Urine 34 on 2026-10-27; Cholesterol [Mass/volume] in Serum or Plasma 152 on 2026-10-27; Cholesterol in HDL [Mass/volume] in Serum or Plasma 39 on 2026-10-27; Triglyceride [Mass/volume] in Serum or Plasma 146 on 2026-10-27; Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation 84 on 2026-10-27; Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma 38 on 2026-02-16; Thyrotropin [Units/volume] in Serum or Plasma 1.8 on 2026-02-16; Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma 312 on 2026-02-16; FEV1 --pre bronchodilation 2.95 on 2026-10-27; FEV1 --post bronchodilation 3.42 on 2026-10-27; FEV1 measured/predicted 77 on 2026-10-27; FEV1/FVC 0.66 on 2026-10-27; FEV1/FVC --post bronchodilation 0.75 on 2026-10-27; Fractional concentration of exhaled nitric oxide 44 on 2026-10-27; Total score [ACT] 15 on 2026-10-27 [S]
Strengths and supports: Supports: his brother monks and disciples, who share his daily life; his faith and practice. He wants his care to fit his vows and his duties, and he alone decides it [S]
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Thirst, frequent urination day and night, tiredness and about 4 kg weight loss over two months, with a random glucose of 246 mg/dL; told by physicians a year ago that he had diabetes, never confirmed with modern tests or treated except by diet. Diabetes to be confirmed and classified (type 2, type 1 or slowly progressive autoimmune diabetes) with A1c, fasting glucose, GAD antibodies and C-peptide | resolved | confirmed | R73.9 | S — Synthetic presenting problem anchored to his documented diabetes of the year before. Superseded by the diagnosis at the second visit. |
| Type 2 diabetes: A1c 9.4 percent and fasting glucose 172 mg/dL, with symptoms; GAD65 antibodies negative and fasting C-peptide preserved (2.6 ng/mL); no ketones. BMI 24.6, in the range where ADA screens Asian Americans. Classified as type 2, not type 1 or slowly progressive autoimmune diabetes | active | confirmed | E11.65 | S — Synthetic modern confirmation and classification linked to his documented diabetes. |
| Moderately increased albuminuria on a first sample (urine albumin-to-creatinine ratio 46 mg/g), eGFR normal; to be confirmed on two of three samples over three to six months | resolved | confirmed | R80.9 | S — Synthetic finding linked to his documented albuminuria; superseded when diabetic kidney disease was confirmed. |
| Raised blood pressure in clinic (138/86, average of two readings) without a diagnosis of hypertension; home readings to be taken | resolved | confirmed | R03.0 | S — Synthetic finding; not a claim about his real blood pressure. |
| Hypertension, stage 1: clinic 138/86, 136/86 and 134/84; home average 136/86 over seven days; with moderately increased albuminuria and diabetes | active | confirmed | I10 | S — Synthetic finding of the modern episode; not a claim about his real blood pressure, which was never recorded. |
| Long-standing difficulty falling asleep: by his own account he has never been able to fall asleep on getting into bed and lies awake for two hours or more most nights; worse lately with waking to pass urine; rises before dawn for meditation | active | confirmed | G47.00 | S — Synthetic modern problem linked to his documented lifelong difficulty falling asleep. |
| Mixed hyperlipidemia: LDL cholesterol 132 mg/dL, triglycerides 228, HDL 36 | active | confirmed | E78.2 | S — Synthetic cardiovascular risk factor. |
| Attacks of wheeze and breathlessness for three weeks since coming down from the mountains to the damp plains, the worst last night with a sense of suffocation: peak flow 330 L/min (56 percent of predicted), oxygen saturation 94 percent, rising to 410 L/min after bronchodilator; no fever, edema or chest pain; chest X-ray and ECG without heart failure or pneumonia. Asthma to be confirmed with spirometry | resolved | confirmed | R06.2 | S — Synthetic presenting problem anchored to his documented suffocating attacks of asthma on his return to Belur. Superseded by the diagnosis a week later. |
| Asthma, adult onset, confirmed: FEV1 2.95 L (77 percent predicted) rising 470 mL (16 percent) after bronchodilator, FEV1/FVC 0.66 rising to 0.75; FeNO 44 ppb; brought on by damp air and smoke; one moderate attack treated with prednisone | active | confirmed | J45.40 | S — Synthetic modern confirmation linked to his documented attacks of asthma. |
| Diabetic kidney disease, CKD stage G1 A2: moderately increased albuminuria on three samples over eight months (46, 41 and 34 mg/g) with eGFR above 90 | active | confirmed | E11.21 | S — Synthetic modern diagnosis linked to his documented albuminuria and Bright's disease; not a claim about the cause of his real kidney disease. |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-02-09 | Glucose [Mass/volume] in Serum or Plasma | 246 | mg/dL | Random sample; 200 mg/dL or more with symptoms suggests diabetes | High | S |
| 2026-02-09 | Sodium [Moles/volume] in Serum or Plasma | 136 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-02-09 | Potassium [Moles/volume] in Serum or Plasma | 4.3 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-02-09 | Creatinine [Mass/volume] in Serum or Plasma | 0.96 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-02-09 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 106 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-02-09 | Hemoglobin [Mass/volume] in Blood | 14.6 | g/dL | 13.5-17.5 g/dL | Normal | S |
| 2026-02-09 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 0 | {score} | S | ||
| 2026-03-09 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 3 | {score} | S | ||
| 2026-03-09 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 2 | {score} | S | ||
| 2026-03-09 | Total score [AUDIT-C] | 0 | {score} | S | ||
| 2026-10-20 | Maximum expiratory gas flow Respiratory system airway by Peak flow meter | 330 | L/min | 80 percent of his predicted 590 L/min | Low | S |
| 2026-02-16 | Hemoglobin A1c/Hemoglobin.total in Blood | 9.4 | % | Below 5.7% is normal; 6.5% or more diabetes; his target below 7% | High | S |
| 2026-02-16 | Glucose [Mass/volume] in Serum or Plasma | 172 | mg/dL | Fasting; 126 mg/dL or more indicates diabetes | High | S |
| 2026-02-16 | Glutamate decarboxylase 65 Ab [Units/volume] in Serum by Immunoassay | 1.2 | [IU]/mL | Below 5 IU/mL negative | Normal | S |
| 2026-02-16 | C peptide [Mass/volume] in Serum or Plasma | 2.6 | ng/mL | 0.8-3.5 ng/mL | Normal | S |
| 2026-02-16 | Albumin/Creatinine [Mass Ratio] in Urine | 46 | mg/g | 30 to 299 moderately increased; 300 or more severely increased | High | S |
| 2026-02-16 | Cholesterol [Mass/volume] in Serum or Plasma | 214 | mg/dL | <=199 mg/dL | High | S |
| 2026-02-16 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 36 | mg/dL | 40 mg/dL or more for men | Low | S |
| 2026-02-16 | Triglyceride [Mass/volume] in Serum or Plasma | 228 | mg/dL | <=149 mg/dL | High | S |
| 2026-02-16 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 132 | mg/dL | <=99 mg/dL | High | S |
| 2026-02-16 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 38 | U/L | 7-55 U/L | Normal | S |
| 2026-02-16 | Thyrotropin [Units/volume] in Serum or Plasma | 1.8 | m[IU]/L | 0.4-4 mIU/L | Normal | S |
| 2026-02-16 | Cobalamin (Vitamin B12) [Mass/volume] in Serum or Plasma | 312 | pg/mL | 232-1245 pg/mL | Normal | S |
| 2026-03-23 | Potassium [Moles/volume] in Serum or Plasma | 4.6 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-03-23 | Creatinine [Mass/volume] in Serum or Plasma | 1 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-03-23 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 101 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-03-23 | Albumin/Creatinine [Mass Ratio] in Urine | 41 | mg/g | 30 to 299 moderately increased; 300 or more severely increased | High | S |
| 2026-10-27 | Hemoglobin A1c/Hemoglobin.total in Blood | 6.9 | % | Below 5.7% is normal; 6.5% or more diabetes; his target below 7% | High | S |
| 2026-10-27 | Glucose [Mass/volume] in Serum or Plasma | 124 | mg/dL | Fasting; 126 mg/dL or more indicates diabetes | High | S |
| 2026-10-27 | Albumin/Creatinine [Mass Ratio] in Urine | 34 | mg/g | 30 to 299 moderately increased; 300 or more severely increased | High | S |
| 2026-10-27 | Potassium [Moles/volume] in Serum or Plasma | 4.5 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-10-27 | Creatinine [Mass/volume] in Serum or Plasma | 0.98 | mg/dL | 0.74-1.35 mg/dL | Normal | S |
| 2026-10-27 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 103 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-10-27 | Cholesterol [Mass/volume] in Serum or Plasma | 152 | mg/dL | <=199 mg/dL | Normal | S |
| 2026-10-27 | Cholesterol in HDL [Mass/volume] in Serum or Plasma | 39 | mg/dL | 40 mg/dL or more for men | Low | S |
| 2026-10-27 | Triglyceride [Mass/volume] in Serum or Plasma | 146 | mg/dL | <=149 mg/dL | Normal | S |
| 2026-10-27 | Cholesterol in LDL [Mass/volume] in Serum or Plasma by calculation | 84 | mg/dL | <=99 mg/dL | Normal | S |
| 2026-10-27 | FEV1 --pre bronchodilation | 2.95 | L | Lower limit of normal; predicted 3.85 L; lower limit of normal 3.10 L (GLI Global race-neutral equations) | Low | S |
| 2026-10-27 | FEV1 --post bronchodilation | 3.42 | L | Lower limit of normal; predicted 3.85 L; lower limit of normal 3.10 L (GLI Global race-neutral equations) | Normal | S |
| 2026-10-27 | FEV1 measured/predicted | 77 | % | GLI Global race-neutral equations | Low | S |
| 2026-10-27 | FEV1/FVC | 0.66 | {ratio} | Lower limit of normal for his age (GLI Global) | Low | S |
| 2026-10-27 | FEV1/FVC --post bronchodilation | 0.75 | {ratio} | Lower limit of normal for his age (GLI Global) | Normal | S |
| 2026-10-27 | Fractional concentration of exhaled nitric oxide | 44 | [ppb] | Above 50 ppb high; 25 to 50 intermediate (ATS) | High | S |
| 2026-10-27 | Total score [ACT] | 15 | {score} | S | ||
| 2026-10-27 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | S |
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-02-09 | Body height | 172 | cm | S |
| 2026-02-09 | Body weight | 73 | kg | S |
| 2026-02-09 | Body mass index (BMI) [Ratio] | 24.7 | kg/m2 | S |
| 2026-02-09 | Systolic blood pressure | 138 | mm[Hg] | S |
| 2026-02-09 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-02-09 | Heart rate | 84 | /min | S |
| 2026-02-09 | Respiratory rate | 16 | /min | S |
| 2026-02-09 | Body temperature | 36.8 | Cel | S |
| 2026-02-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-02-16 | Body height | 172 | cm | S |
| 2026-02-16 | Body weight | 72.8 | kg | S |
| 2026-02-16 | Body mass index (BMI) [Ratio] | 24.6 | kg/m2 | S |
| 2026-02-16 | Systolic blood pressure | 136 | mm[Hg] | S |
| 2026-02-16 | Diastolic blood pressure | 86 | mm[Hg] | S |
| 2026-02-16 | Heart rate | 80 | /min | S |
| 2026-02-16 | Respiratory rate | 16 | /min | S |
| 2026-02-16 | Body temperature | 36.7 | Cel | S |
| 2026-02-16 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-09 | Body height | 172 | cm | S |
| 2026-03-09 | Body weight | 73.4 | kg | S |
| 2026-03-09 | Body mass index (BMI) [Ratio] | 24.8 | kg/m2 | S |
| 2026-03-09 | Systolic blood pressure | 134 | mm[Hg] | S |
| 2026-03-09 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-03-09 | Heart rate | 76 | /min | S |
| 2026-03-09 | Respiratory rate | 14 | /min | S |
| 2026-03-09 | Body temperature | 36.7 | Cel | S |
| 2026-03-09 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-03-23 | Body height | 172 | cm | S |
| 2026-03-23 | Body weight | 73.8 | kg | S |
| 2026-03-23 | Body mass index (BMI) [Ratio] | 24.9 | kg/m2 | S |
| 2026-03-23 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-03-23 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2026-03-23 | Heart rate | 74 | /min | S |
| 2026-03-23 | Respiratory rate | 14 | /min | S |
| 2026-03-23 | Body temperature | 36.6 | Cel | S |
| 2026-03-23 | Oxygen saturation in Arterial blood by Pulse oximetry | 98 | % | S |
| 2026-10-20 | Body height | 172 | cm | S |
| 2026-10-20 | Body weight | 74.6 | kg | S |
| 2026-10-20 | Body mass index (BMI) [Ratio] | 25.2 | kg/m2 | S |
| 2026-10-20 | Systolic blood pressure | 132 | mm[Hg] | S |
| 2026-10-20 | Diastolic blood pressure | 82 | mm[Hg] | S |
| 2026-10-20 | Heart rate | 108 | /min | S |
| 2026-10-20 | Respiratory rate | 24 | /min | S |
| 2026-10-20 | Body temperature | 36.9 | Cel | S |
| 2026-10-20 | Oxygen saturation in Arterial blood by Pulse oximetry | 94 | % | S |
| 2026-10-27 | Body height | 172 | cm | S |
| 2026-10-27 | Body weight | 74.8 | kg | S |
| 2026-10-27 | Body mass index (BMI) [Ratio] | 25.3 | kg/m2 | S |
| 2026-10-27 | Systolic blood pressure | 126 | mm[Hg] | S |
| 2026-10-27 | Diastolic blood pressure | 78 | mm[Hg] | S |
| 2026-10-27 | Heart rate | 82 | /min | S |
| 2026-10-27 | Respiratory rate | 16 | /min | S |
| 2026-10-27 | Body temperature | 36.6 | Cel | S |
| 2026-10-27 | Oxygen saturation in Arterial blood by Pulse oximetry | 97 | % | S |
| Date | Purpose | Status | Provenance |
|---|---|---|---|
| 2026-02-09 | New patient visit for thirst, frequent urination, tiredness and weight loss in a 35-year-old monk told of diabetes a year ago and never tested: examination, random glucose and urine tests, and planning of fasting tests to confirm and classify diabetes; long-standing insomnia; raised blood pressure | finished | S |
| 2026-02-16 | Diagnosis visit with the endocrinology consultation: A1c, fasting glucose, GAD antibodies, C-peptide, urine albumin, lipids and B12; type 2 diabetes confirmed; metformin by shared decision; nutrition and fasting plans | finished | S |
| 2026-03-23 | Five-week diabetes review before a long journey: glucose log, metformin dose, kidney function and potassium on losartan, repeat urine albumin, retinal photographs, statin, and a travel and fasting plan | finished | S |
| 2026-10-27 | Review after seven months away and a week after an asthma attack: A1c, kidneys, lipids, spirometry with bronchodilator response and FeNO; asthma and diabetic kidney disease confirmed; empagliflozin and maintenance-and-reliever inhaler; fasting plan for the coming festival | finished | S |
| 2026-03-09 | Periodic preventive visit | finished | S |
| 2026-10-20 | Same-day sick visit for an asthma attack after returning from the mountains | finished | S |
| Intervention | Status | Guideline | Provenance |
|---|---|---|---|
| Endocrinology consultation in one week, the same day as fasting blood tests, to confirm and classify diabetes (A1c, fasting glucose, GAD antibodies, C-peptide), and advise on treatment that fits his diet, his religious fasts and his travel | completed | GL-ADA-DX-2026, GL-ADA-PHARM-2026, GL-CMID-2026 | S |
| Diagnostic tests in one week, fasting: A1c, fasting plasma glucose, GAD65 antibodies, C-peptide, urine albumin-to-creatinine ratio, lipid panel, ALT, TSH and vitamin B12; urine ketones negative today; drink water freely while thirsty and avoid waterless fasts until the results are known; return the same day if vomiting, abdominal pain or drowsiness | completed | GL-ADA-DX-2026, GL-ADA-PHARM-2026, GL-CMID-2026, GL-ADA-COMORB-2026 | S |
| Home blood pressure readings twice daily for a week with a validated upper-arm cuff, because clinic readings are raised | completed | GL-ADA-CVD-2026, GL-CMID-2026 | S |
| Insomnia: sleep diary for two weeks, screening for sleep apnea, and cognitive behavioral therapy for insomnia adapted to his pre-dawn meditation; no sleeping tablets, by his preference; nocturia to be reviewed once glucose is treated | completed | GL-ACP-INS-2016, GL-AASM-INS-2021 | S |
| Metformin extended-release with the evening meal, titrated to 2000 mg, chosen by shared decision over early combination therapy or an injected GLP-1 receptor agonist; home glucose meter; diabetes education and medical nutrition therapy for a mostly vegetarian plan built on his monastery meals, his choices and his fasts; sulfonylureas avoided because of fasting | completed | GL-ADA-PHARM-2026, GL-ADA-BEH-2026, GL-SA-PLANT-2022, GL-CMID-2026 | S |
| Religious fasting plan adapted from IDF-DAR risk stratification: fasts with fruit, milk and water allowed; waterless fasts only once glucose is steady, with hydration; metformin with the meal that ends the fast; glucose checks at midday and before breaking the fast; break the fast below 70 or above 300 mg/dL or when unwell | completed | GL-IDF-DAR-2021, GL-ADA-BEH-2026 | S |
| Vaccines for an adult with diabetes: influenza and COVID-19 each season, PCV20 once, hepatitis B (two doses) and Tdap | completed | GL-CDC-IMZ-MC-2026, GL-CDC-IMZ-2026 | S |
| Hypertension with albuminuria: losartan 25 mg daily (an ARB rather than an ACE inhibitor, to avoid cough), less salt, home readings, potassium and creatinine two weeks after starting | completed | GL-ADA-CVD-2026, GL-ADA-CKD-2026, GL-CMID-2026 | S |
| Cardiovascular prevention: atorvastatin 10 mg daily at 35 with diabetes, South Asian ancestry, albuminuria and hypertension, by his choice; lipid panel six to twelve weeks after starting | completed | GL-ADA-CVD-2026, GL-SOUTHASIAN-2013, GL-CMID-2026 | S |
| Travel plan for months away: medicine and test-strip supply, sick-day rules (hold metformin and losartan when vomiting, with diarrhea or unable to drink), monthly messages with readings, and A1c, urine albumin and lipids at three months wherever he is | completed | GL-ADA-PHARM-2026, GL-CMID-2026 | S |
| Asthma attack in a man with diabetes: prednisone 40 mg for five days with glucose checks before breakfast and the evening meal and a call for readings above 300 mg/dL; as-needed budesonide-formoterol until spirometry; review within a week | completed | GL-GINA-2025, GL-ADA-GLY-2026 | S |
| Diabetic kidney disease G1 A2: empagliflozin 10 mg each morning, skipped on waterless fast days and stopped with metformin when unable to eat or drink; losartan continued; potassium, creatinine and urine albumin in three months, then every six months | completed | GL-ADA-CKD-2026, GL-KDIGO-CKD-2024, GL-IDF-DAR-2021 | S |
| Asthma on GINA track 1, step 3: budesonide-formoterol one inhalation twice daily and as needed with a spacer, a written action plan, a smoke-free room, review in four to six weeks and spirometry in three months | completed | GL-GINA-2025, GL-NAEPP-2020, GL-CMID-2026 | S |
| Goal | Target | Status | Outcome | Provenance |
|---|---|---|---|---|
| Diabetes confirmed and classified within a week | 2026-02-16 | completed | Type 2 diabetes confirmed by A1c 9.4 percent and fasting glucose 172 mg/dL; GAD65 antibodies negative and C-peptide preserved | S |
| A1c below 7 percent without hypoglycemia, in a way that fits his diet and fasts | 2026-10-27 | completed | A1c 6.9 percent on metformin; no hypoglycemia; fasts kept safely | S |
| Blood pressure below 130/80 | 2026-03-23 | completed | Home 128/80 and clinic 128/80 two weeks after starting losartan | S |
| Albuminuria reduced and kidney function preserved | 2027-01-26 | active | Urine albumin-to-creatinine ratio down from 46 to 34 mg/g; eGFR 103; empagliflozin started | S |
| Falling asleep within 30 minutes on most nights | 2026-12-08 | active | About 45 minutes after four of six sessions | S |